According to filings with the U.S. Securities and Exchange Commission, Ora Biomedical is raising up to $1,020,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mitchell Lee played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ora Biomedical
Ora Biomedical, Inc. is a new pharmaceutical company in the longevity biotechnology sector that identifies and characterizes healthy aging therapeutics for further clinical and commercial development. Ora Biomedical separates itself from other longevity biotech companies by building in large-scale drug discovery and validation at the core of our scientific operations. With robust preclinical discovery at the heart of our approach, we identify novel aging targets and new interventions for known targets. Most importantly, we will leverage large-scale operations to perform drug studies that combine known and novel healthy aging interventions to identify those that produce breakthrough increases in healthy lifespan and/or mitigate disease-mediated pathology.

To learn more about Ora Biomedical, visit http://orabiomedical.com/

Contact:
Mitchell Lee, Chief Executive Officer
206-839-6250
https://www.linkedin.com/in/mitchell-lee-54296143/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.